Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: “Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications”

Not available.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-09-17
DOI
https://doi.org/10.3324/haematol.2026.301889
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: “Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications”

Yi-Lun Wang, Tang-Her Jaing
Haematologica
Lymphoma Diagnosis and Treatment
article

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: “Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications”

Yi-Lun Wang, Tang-Her Jaing
article en

Abstract

No abstract available for this paper.

Haematologica
Chang Gung Memorial Hospital (TW), Linkou Chang Gung Memorial Hospital (TW)
Good health and well-being
Openalex Percentile: Top 12%
Lymphoma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: “Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications” — Yi-Lun Wang, Tang-Her Jaing · Haematologica (2026) | TGRS Research Map | TGRS